全文获取类型
收费全文 | 8975篇 |
免费 | 406篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 180篇 |
儿科学 | 194篇 |
妇产科学 | 220篇 |
基础医学 | 1730篇 |
口腔科学 | 128篇 |
临床医学 | 669篇 |
内科学 | 1584篇 |
皮肤病学 | 174篇 |
神经病学 | 882篇 |
特种医学 | 633篇 |
外科学 | 1296篇 |
综合类 | 52篇 |
一般理论 | 1篇 |
预防医学 | 429篇 |
眼科学 | 213篇 |
药学 | 566篇 |
中国医学 | 11篇 |
肿瘤学 | 444篇 |
出版年
2021年 | 95篇 |
2020年 | 68篇 |
2019年 | 73篇 |
2018年 | 105篇 |
2017年 | 96篇 |
2016年 | 110篇 |
2015年 | 133篇 |
2014年 | 195篇 |
2013年 | 295篇 |
2012年 | 358篇 |
2011年 | 371篇 |
2010年 | 249篇 |
2009年 | 214篇 |
2008年 | 351篇 |
2007年 | 360篇 |
2006年 | 389篇 |
2005年 | 393篇 |
2004年 | 351篇 |
2003年 | 342篇 |
2002年 | 355篇 |
2001年 | 164篇 |
2000年 | 198篇 |
1999年 | 182篇 |
1998年 | 120篇 |
1997年 | 80篇 |
1996年 | 73篇 |
1995年 | 75篇 |
1994年 | 67篇 |
1992年 | 105篇 |
1991年 | 110篇 |
1990年 | 91篇 |
1989年 | 72篇 |
1988年 | 57篇 |
1987年 | 64篇 |
1986年 | 65篇 |
1985年 | 58篇 |
1982年 | 55篇 |
1978年 | 55篇 |
1976年 | 55篇 |
1973年 | 67篇 |
1933年 | 72篇 |
1932年 | 62篇 |
1931年 | 58篇 |
1930年 | 77篇 |
1929年 | 55篇 |
1928年 | 60篇 |
1927年 | 58篇 |
1925年 | 65篇 |
1924年 | 60篇 |
1922年 | 53篇 |
排序方式: 共有9406条查询结果,搜索用时 15 毫秒
991.
Adrienne H Brouwers Julli?tte E M van Eerd Cathelijne Frielink Egbert Oosterwijk Wim J G Oyen Frans H M Corstens Otto C Boerman 《Journal of nuclear medicine》2004,45(2):327-337
Radioimmunotherapy (RIT) can be performed with various radionuclides. We tested the stability, biodistribution, and therapeutic efficacy of various radioimmunoconjugates ((131)I, (88/90)Y, (177)Lu, and (186)Re) of chimeric antirenal cell cancer monoclonal antibody G250 (mAb cG250) in nude mice with subcutaneous renal cell cancer (RCC) tumors. METHODS: The (88/90)Y and (177)Lu labeling procedures of cG250 conjugated with cyclic diethylenetriaminepentaacetic acid anhydride (cDTPA), isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), or 1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) were characterized. Stability of the labeled conjugates in plasma at 37 degrees C was assessed. Biodistribution and therapeutic efficacy of labeled cG250 were compared in nude mice with SK-RC-52 human RCC xenografts. RESULTS: Both SCN-Bz-DTPA and DOTA were stable in vitro (<5% release of the radiolabel during 14 and 21 d of incubation) and in vivo (uptake in bone = 1.5 percentage injected dose per gram [%ID/g] at 7 d after injection) when used to label (88)Y or (177)Lu to cG250. The DOTA conjugate was slightly but significantly more stable than SCN-Bz-DTPA at 7 d after injection. In vivo, these cG250 preparations showed high tumor uptake (70 +/- 15 %ID/g +/- SD at 7 d after injection). Maximum tumor uptake for (125)I-cG250 and (186)Re-mercaptoacetyltriglycine-(MAG3)-cG250 (<20 +/- 3 %ID/g +/- SD) was reached at 3 d after injection and was much lower in comparison with cG250 labeled with the residualizing radionuclides. Because the highest specific activities could be prepared using SCN-Bz-DTPA, and relatively low protein doses of cG250 could be administered without saturating the tumor, cG250-SCN-Bz-DTPA conjugates were used in RIT studies. In RIT experiments at maximum tolerated dose, tumor growth was delayed most effectively by cG250 labeled with (177)Lu, next most effectively by (90)Y and (186)Re (which were approximately equal), and least by (131)I (delayed by approximately 185, 125, 90, and 25 d, respectively). The best median survival (300 d) was observed for (177)Lu-SCN-Bz-DTPA-cG250. Median survival for control groups was <150 d. CONCLUSION: DOTA-conjugated radiolabeled antibodies were the most stable radioimmunoconjugates in vitro and in vivo as manifested by the lowest bone uptake. However, specific activity was higher for SCN-Bz-DTPA. The RIT studies clearly showed that the therapeutic efficacy of mAb cG250 labeled with (177)Lu, (90)Y, or (186)Re was superior to that of (131)I-cG250. The residualizing radionuclides (177)Lu and (90)Y led to higher radiation doses to the tumor and most likely are better candidates than conventionally radiolabeled (131)I for RIT with cG250 in patients with RCC. 相似文献
992.
993.
Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer. 总被引:1,自引:0,他引:1
Jan Harder Oliver Kummer Manfred Olschewski Florian Otto Hubert Erich Blum Oliver Opitz 《Cancer epidemiology, biomarkers & prevention》2007,16(10):2097-2100
Serum carbohydrate antigen 19-9 (CA 19-9) has been identified as biochemical marker for biliary tract cancer (BTC). The purpose of this study was to evaluate its value as a treatment response marker and its value as a prognostic parameter in patients with unresectable BTC. We analyzed 70 patients with BTC treated with chemotherapy. CA 19-9 levels before and after two treatment courses were analyzed with respect to their effect on treatment response. Patients were categorized into two subgroups according to biliary stenting: patients without endoscopic intervention or biliary drainage (non-stent subgroup) and patients with endoluminal stenting (stent subgroup). Pretreatment CA 19-9 levels were prognostic with respect to overall survival for the entire study population. Patients with CA 19-9 levels above the median of 300 units/mL had a nearly 3-fold risk for early death (hazard ratio, 2.92; 95% confidence interval, 1.51-5.64; adjusted P = 0.002) as compared with patients with CA 19-9 levels 相似文献
994.
Ohne ZusammenfassungMit 7 Textabbildungen. 相似文献
995.
Ohne Zusammenfassung 相似文献
996.
997.
Otto Rehm 《Journal of neurology》1933,132(3-4):114-122
Ohne ZusammenfassungNach einem Vortrag im Verein der Irren- und Nervenärzte Niedersachsens und Westfalens in Hannover am 6. V. 1933. 相似文献
998.
999.
1000.